Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Titel:
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Auteur:
Kelley, Robin Kate Rimassa, Lorenza Cheng, Ann-Lii Kaseb, Ahmed Qin, Shukui Zhu, Andrew X Chan, Stephen L Melkadze, Tamar Sukeepaisarnjaroen, Wattana Breder, Valery Verset, Gontran Gane, Edward Borbath, Ivan Rangel, Jose David Gomez Ryoo, Baek-Yeol Makharadze, Tamta Merle, Philippe Benzaghou, Fawzi Banerjee, Kamalika Hazra, Saswati Fawcett, Jonathan Yau, Thomas
Verschenen in:
Lancet oncology
Paginering:
Jaargang 23 () nr. 8 pagina's 995-1008
Jaar:
2022
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license